Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria (CSU) up to week 52 in the REMIX-1/-2 studies
Early and sustained efficacy of remibrutinib in adult patients with CSU: Pooled analysis of REMIX‑1/-2
Remibrutinib-treated patients with CSU who achieve well-controlled disease activity reach this by week 3 in the majority of patients: Results from REMIX-1/-2 studies
Efficacy of remibrutinib in patients with CSU by demographics and baseline characteristics: Pooled analysis from REMIX-1/-2 studies
Urticaria Voices China: A real-world study design to assess the perspectives of Chinese patients and physicians on the burden and treatment of chronic urticaria
Urticaria Voices (China): A survey on physicians’ perception of chronic urticaria and its treatment in China
Remibrutinib improves urticaria symptoms, quality of life and sleep: An analysis from REMIX-1/-2 studies
The impact of remibrutinib on urticaria control in patients with chronic spontaneous urticaria: Long-term results from the REMIX-1/-2 phase 3 trials
Remibrutinib treatment has no clinical impact on mean blood cell counts in patients with chronic spontaneous urticaria: Pooled safety analysis from REMIX-1 and REMIX-2 studies
Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52-week treatment results from the phase 3 REMIX studies
Remibrutinib improves chronic spontaneous urticaria independent of baseline immunoglobulin E levels in the phase 3 REMIX studies
Improvement across work productivity and quality of life with remibrutinib treatment in patients with chronic spontaneous urticaria in the REMIX-1/2 trials
Impact of remibrutinib treatment on disease activity status and Dermatology Life Quality Index (DLQI) subdomains in patients with chronic spontaneous urticaria in the REMIX-1/-2 studies
Prescribing patterns and treatment outcome of dermatologists and allergists for chronic spontaneous urticaria: Urticaria Voices study
Out-of-pocket expenses in patients with chronic spontaneous urticaria: Results from Urticaria Voices
Patient journey and disease burden in chronic inducible urticaria (CIndU): Analysis from the Urticaria Voices study
Effect of remibrutinib on sleep and daily activities in patients with chronic spontaneous urticaria: Results from the phase 3 studies
Safety and efficacy of remibrutinib in Japanese patients with chronic spontaneous urticaria (BISCUIT study interim analysis)
Physician’s perspective on the burden of CSU for patients and unmet need while treating CSU: Country-wide data from Urticaria Voices
Safety of remibrutinib in patients with chronic spontaneous urticaria: Results from the phase 3 REMIX-1 and REMIX-2 studies
CSU disease activity band shift after long-term treatment with remibrutinib in the phase 3 REMIX-1 and REMIX-2 studies
Frequency of angioedema in patients with chronic spontaneous urticaria: Report from the Urticaria Voices study
No clinically meaningful impact of remibrutinib on immunoglobulin levels or infections in chronic spontaneous urticaria
Impact of remibrutinib on Dermatology-Related Quality of Life (DLQI) in patients with chronic spontaneous urticaria in the phase 3 REMIX-1 and REMIX-2 studies
Early and long-term efficacy and safety of remibrutinib in patients with chronic spontaneous urticaria: 52-week data from the Phase 3 REMIX-1 and REMIX-2 studies
REMIX-1/-2: Early symptom improvements with remibrutinib in chronic spontaneous urticaria from week 1
Efficacy of remibrutinib on patients with chronic spontaneous urticaria with or without prior exposure to biologics in the phase 3 REMIX-1 and REMIX-2 studies
Effect of remibrutinib treatment on disease activity in chronic spontaneous urticaria: Data from the phase 3 REMIX-1 and REMIX-2 studies
Worldwide experiences and unmet needs of patients with chronic spontaneous urticaria and treating physicians: The Urticaria Voices study
© Copyright 2025 Novartis Pharma AG